FAS and Lymphadenopathy: Suggestive evidence for an in vivo Fas/FasL role as a negative regulator of T cell activation is derived from lpr mice that overexpress p21 in T cells, as high p21 levels controlled lpr T cell activation and proliferation as well as autoimmunity and lymphadenopathy.